11.24 Daily Digest
Leave a CommentEARNINGS
Medtronic Reports 2Q10 revenue of $3.838 Billion, +8%. Neuromodulation revenue of $384MM, +12% from 2Q09, driven by strong sales of Activa® PC and RC Deep Brain Stimulation systems for movement disorders, and InterStim® Therapy used to treat urinary and bowel incontinence. Learn More
11.23 Daily Digest
Leave a CommentFEATURED PROCEDURES
Sacral Neuromodulation Control Curess 55-Year Old Women’s Incontinence (UK). Sue Jacobs passes on repeat Botox injections to bladder sides and involves a 20% risk of paralysing the bladder muscles, (at which points patients require a catheter to pass urine.) and chooses sacral neuromodulation. Learn More
11.22 Daily Digest
Leave a CommentNo market news.
11.21 Daily Digest
FEATURED EXECUTIVES
MicroTransponder CEO Will Rosellini Named Graduate Student Entrepreneur of the Year by the Entrepreneurs’ Organization (EO). Rosellini was recognized for his vision and drive to create a dynamic neurostimulation company that is developing products to treat a range of neurological disorders including tinnitus, stroke, Parkinson’s disease, and chronic pain. Learn More
11.20 Daily Digest
CONFERENCES/FEATURED COMPANIES
Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference. Dan Moore, President and Chief Executive Officer, and Greg Browne, Chief Financial Officer, will present in a conference session on Wednesday, December 2, 2009 at 12:00 PM EST. Learn More
11.19 Daily Digest
PRODUCT INTRODUCTIONS/UPDATES
St. Jude Medical, Inc. Announces: 62-Year-Old Man Becomes First Patient in China Implanted with the Eon™ neurostimulator, a Rechargeable Neurostimulator for Chronic Pain. The Eon neurostimulator, which is the first rechargeable spinal cord stimulator to be approved for use in China. Learn More
11.18 Daily Digest
EARNINGS
Cyberonics Reports Record Sales and Operating Profit in Fiscal 2010 Second Quarter. Net sales of $40.7MM, a 13% increase from $36.0MM. U.S. and international epilepsy unit sales increased by 6% and 13%, respectively. The company also expects a non-cash tax benefit 2Q10 of $40.5 million resulting from the reversal of its tax valuation allowance related to net operating losses. Learn More
FUNDING
BIDMC Scientists Awarded 1.5MM Grants From Michael J. Fox Foundation for Parkinson’s research. Pascual-Leone, Director of BIDMC’s Berenson-Allen Center for Noninvasive Brain Stimulation, will oversee the 3 year grant to investigate the use of repetitive transcranial magnetic stimulation (rTMS) therapy to control symptoms of Parkinson’s disease. As part of the study, 160 patients will be enrolled in clinical trials at BIDMC and at three other North American centers including the University of Florida in Gainesville, the University of California in Los Angeles, and the Toronto (Canada) Western Research Institute-University of Toronto. Learn More
11.17 Daily Digest
EARNINGS
Medtronic Inc (NYSE:MDT) to Release Q2 2010 Earnings November 24. The financial results will be released at 6:15 am CT at Medtronic.com/newsroom. The company will hold a conference call at 7:00 am CT that morning to review the financial results. Learn More
FEATURED COMPANIES/CLINICAL
Brainsgate’s Investigational neurostimulation device aims to reduce stroke damage. The trial, called impact-24 (Implant for Augmentation of CBF Trial in a 24 hour window), is a multi-center, randomized, double blind study taking place over the next two years. Methodist is one of six locations in the United States to offer this feasibility study. Learn More
FEATURED COMPANIES/PRODUCTS
Urgent(R) PC and Macroplastique(R) Abstracts Accepted for Presentation at Society for Urodynamics and Female Urology 2010 Annual Meeting. Presentations accepted were for both Uroplasty’s Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products. Learn More
11.14-11.16 Daily Digest
No market news.
